{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T08:55:29Z","timestamp":1770540929025,"version":"3.49.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T00:00:00Z","timestamp":1639353600000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Age-related macular degeneration (AMD) is a disease that causes damage in the macular region of the retina, leading to irreversible blindness. This study aims to understand the profile and care of patients with AMD and its cost at the Brazilian public health system to identify AMD-care needs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is a retrospective observational study of AMD with real-world data from the Brazilian public healthcare system, using DATASUS claim databases. Patients with AMD were selected from 01\/Jan\/2014 to 31\/Jan\/2020; had at least one claim of ICD10 code H35.3 (Degeneration of macula and posterior pole), and were submitted to one of two procedures exclusively available for AMD patients - optical coherence tomography (OCT) and medical treatment of retinal disease (antiangiogenic); aged \u226518\u2009years at first ICD10 claim, and presenting at least 1 year of follow-up in the database. We described patients\u2019 characteristics, healthcare resource utilization and cost, and the antiangiogenic intravitreal treatment received by AMD patients, including the number of doses and interval time between them.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Patients searching for AMD treatment since 2014 were mostly females (59%), white (61%), and a mean age of 72\u2009years. They were mainly located in the Southeast (87%), and few patients were found in the North (1%) and Central-West (1.5%) regions, probably reflecting where the Brazilian guideline to treat AMD (<jats:italic>Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas<\/jats:italic> - PCDT) was incorporated as routine care for AMD. The average antiangiogenic dose of 2.5 antiangiogenic therapies within a year was below the expected. Most injections had an interval time of 20 to 40\u2009days between doses, although some patients were treated more than 100\u2009days. Another setback is that patients traveled longer distances for OCT and antiangiogenic treatment than overall AMD-healthcare, between 10 and 100\u2009km.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>AMD patients seem to be undertreated, as they receive a mean of 2.5 doses of antiangiogenic treatment within a year. Inequalities among regions are evident, as the Southeast and South regions comprise almost all patients receiving the treatment from the public health system, probably reflecting the region with more access to AMD care according to PCDT recommendations.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12886-021-02181-1","type":"journal-article","created":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T05:02:19Z","timestamp":1639371739000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Age-related macular degeneration and resource utilization in the Brazilian public healthcare system: a real-world retrospective study"],"prefix":"10.1186","volume":"21","author":[{"given":"Liane","family":"Touma-Falci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos Augusto","family":"Moreira-Neto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre Chater","family":"Taleb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcela Bach","family":"Prieto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thais","family":"Packer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio Cesar Barbour","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina Gabriela","family":"Birck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilherme Silva","family":"Julian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco Jose","family":"Forestiero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,13]]},"reference":[{"key":"2181_CR1","volume-title":"Garner and Klintworth\u2019s Pathobiology of Ocular Disease","author":"LGR Lim","year":"2008","unstructured":"Lim LGR. Age-related macular degeneration. In:  Garner and Klintworth\u2019s Pathobiology of Ocular Disease. 3rd ed; 2008.","edition":"3"},{"issue":"0","key":"2181_CR2","first-page":"1","volume":"0","author":"JM Furtado","year":"2019","unstructured":"Furtado JM, Berezovsky A, Ferraz NN, Mu\u00f1oz S, Fernandes G, Watanabe SS, et al. Prevalence and Causes of Visual Impairment and Blindness in Adults Aged 45 Years and Older from Parintins\u00a0: The Brazilian Amazon Region Eye Survey Prevalence and Causes of Visual Impairment and Blindness in Adults Aged 45 Years and Older from Parintins. Ophthalmic Epidemiol. 2019;0(0):1\u201310.","journal-title":"Ophthalmic Epidemiol"},{"key":"2181_CR3","first-page":"1","volume-title":"Multimorbidity\u00a0: The Brazilian Longitudinal Study of Aging ( ELSI-Brazil )","author":"BP Nunes","year":"2018","unstructured":"Nunes BP, Rog\u00e9rio S, Batista R, Bof F, Iii DA. Multimorbidity\u00a0: The Brazilian Longitudinal Study of Aging ( ELSI-Brazil ); 2018. p. 1\u201312."},{"key":"2181_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2415-9-8","volume":"9","author":"SA Schellini","year":"2009","unstructured":"Schellini SA, Durkin SR, Hoyama E, Hirai F, Cordeiro R, Casson RJ, et al. Prevalence and causes of visual impairment in a Brazilian population\u00a0: The Botucatu eye study. BMC Ophthalmol. 2009;9:1\u20139.","journal-title":"BMC Ophthalmol"},{"issue":"3","key":"2181_CR5","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1590\/S0004-27492008000300013","volume":"71","author":"APMT Oguido","year":"2008","unstructured":"Oguido APMT, Casella AMB, Matsuo T, de Ramos Filho EH, Berbel R, Silva RMA. Prevalence of age-related macular degeneration in Japanese immigrants and their descendants living in Londrina (PR) - Brazil. Arq Bras Oftalmol. 2008;71(3):375\u201380.","journal-title":"Arq Bras Oftalmol"},{"issue":"3","key":"2181_CR6","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1590\/S0004-27492005000500015","volume":"68","author":"FA Romani","year":"2005","unstructured":"Romani FA. Preval\u00eancia de transtornos oculares na popula\u00e7\u00e3o de idosos residentes na cidade de Veran\u00f3polis, RS, Brasil. Arq Bras Oftalmol. 2005;68(3):649\u201355.","journal-title":"Arq Bras Oftalmol"},{"issue":"10153","key":"2181_CR7","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(18)31550-2","volume":"392","author":"P Mitchell","year":"2018","unstructured":"Mitchell P, Liew G, Gopinath B, Wong TY. Age-related macular degeneration. Lancet. 2018;392(10153):1147\u201359. https:\/\/doi.org\/10.1016\/S0140-6736(18)31550-2.","journal-title":"Lancet"},{"issue":"2","key":"2181_CR8","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3390\/jcm4020343","volume":"4","author":"Y Yonekawa","year":"2015","unstructured":"Yonekawa Y, Miller J, Kim I. Age-related macular degeneration: advances in management and diagnosis. J Clin Med. 2015;4(2):343\u201359.","journal-title":"J Clin Med"},{"issue":"2","key":"2181_CR9","first-page":"142","volume":"15","author":"NM Bressler","year":"2002","unstructured":"Bressler NM. Early detection and treatment of neovascular age-related macular degeneration. J Am Board Fam Pract. 2002;15(2):142\u201352.","journal-title":"J Am Board Fam Pract"},{"key":"2181_CR10","first-page":"1","volume-title":"Treatment options for age-related macular degeneration\u00a0: a budget impact analysis from the perspective of the Brazilian public health system","author":"F Tavares","year":"2015","unstructured":"Tavares F, Elias S, Nunes E, Belfort R. Treatment options for age-related macular degeneration\u00a0: a budget impact analysis from the perspective of the Brazilian public health system; 2015. p. 1\u201310."},{"key":"2181_CR11","unstructured":"IBGE. Instituto Brasileiro de Geografia e Estat\u00edstica (Brazilian Institute of Geography and Statistics) [Internet]. 2021 [cited 2021 Apr 13]. Available from: http:\/\/www.ibge.gov.br\/home\/."},{"key":"2181_CR12","volume-title":"Portaria Conjunta n\u00b0 18, de 02 de julho de 2018","author":"Minist\u00e9rio da Sa\u00fade","year":"2018","unstructured":"Minist\u00e9rio da Sa\u00fade. Portaria Conjunta n\u00b0 18, de 02 de julho de 2018. 2018."},{"key":"2181_CR13","unstructured":"Minist\u00e9rio da Sa\u00fade. DATASUS - SIGTAP [Internet]. [cited 2020 Apr 17]. Available from: http:\/\/sigtap.datasus.gov.br\/tabela-unificada\/app\/sec\/inicio.jsp"},{"issue":"5","key":"2181_CR14","first-page":"A321","volume":"20","author":"D Campos","year":"2017","unstructured":"Campos D, Rosim R, Duva A, et al. Brazilian healthcare record linkage (brhc-rlk) \u2013 a record linkage methodology for Brazilian medical claims datasets (DATASUS). Value Health. 2017;20(5):A321.","journal-title":"Value Health"},{"issue":"2","key":"2181_CR15","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X, Cheung CMG, Klein R, Cheng C-Y, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106\u201316.","journal-title":"Lancet Glob Health"},{"issue":"2","key":"2181_CR16","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1590\/S0004-27492005000200014","volume":"68","author":"LPF Santos","year":"2005","unstructured":"Santos LPF, Diniz JR, de Souza Le\u00e3o AC, Sena MF. Degenera\u00e7\u00e3o macular relacionada \u00e0 idade: preval\u00eancia e fatores de risco em dois centros oftalmol\u00f3gicos de refer\u00eancia em Pernambuco. Arq Bras Oftalmol. 2005;68(2):229\u201333.","journal-title":"Arq Bras Oftalmol"},{"issue":"12","key":"2181_CR17","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1016\/j.ophtha.2015.08.002","volume":"122","author":"N Joachim","year":"2015","unstructured":"Joachim N, Mitchell P, Burlutsky G, Kifley A, Wang JJ. The incidence and progression of age-related macular degeneration over 15 years: the Blue Mountains eye study. Ophthalmology. 2015;122(12):2482\u20139.","journal-title":"Ophthalmology."},{"key":"2181_CR18","first-page":"1","volume-title":"Protocolo cl\u00ednico e diretrizes terap\u00eauticas. Degenera\u00e7\u00e3o macular relacionada com a idade (forma neovascular)","author":"FA Figueiredo","year":"2018","unstructured":"Figueiredo FA, Fireman MAA. Protocolo cl\u00ednico e diretrizes terap\u00eauticas. Degenera\u00e7\u00e3o macular relacionada com a idade (forma neovascular). Minist\u00e9rio da Sa\u00fade; 2018. p. 1\u201319."},{"issue":"1","key":"2181_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12889-019-7562-y","volume":"19","author":"SL Sodr\u00e9","year":"2019","unstructured":"Sodr\u00e9 SL, Barbosa IAF, Pacheco IE, Ferreira FDQT, David MA, Nascimento MA, et al. Costs and benefits of bevacizumab vial sharing for the treatment of retinal diseases. BMC Public Health. 2019;19(1):1\u20138.","journal-title":"BMC Public Health"},{"key":"2181_CR20","volume-title":"Custos e benef\u00edcios do compartilhamento do bevacizumabe para o tratamento das doencas vasculares retinianas","author":"SL Sodr\u00e9","year":"2019","unstructured":"Sodr\u00e9 SL. Custos e benef\u00edcios do compartilhamento do bevacizumabe para o tratamento das doencas vasculares retinianas. Universidade Estadual de Campinas; 2019."},{"issue":"2","key":"2181_CR21","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1167\/iovs.10-6431","volume":"52","author":"L Liu","year":"2011","unstructured":"Liu L, Ammar DA, Ross LA, Mandava N, Kahook MY, Carpenter JF. Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling. Investig Ophthalmol Vis Sci. 2011;52(2):1023\u201334.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"2181_CR22","doi-asserted-by":"publisher","first-page":"897","DOI":"10.2147\/OPTH.S207978","volume":"14","author":"M Schargus","year":"2020","unstructured":"Schargus M, Frings A. Issues with intravitreal administration of anti-vegf drugs. Clin Ophthalmol. 2020;14:897\u2013904.","journal-title":"Clin Ophthalmol"},{"issue":"9","key":"2181_CR23","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1007\/s00417-016-3314-1","volume":"254","author":"S Kimura","year":"2016","unstructured":"Kimura S, Morizane Y, Toshima S, Hosogi M, Kumase F, Hosokawa M, et al. Efficacy of vitrectomy and inner limiting membrane peeling in age-related macular degeneration resistant to anti-vascular endothelial growth factor therapy, with vitreomacular traction or epiretinal membrane. Graefes Arch Clin Exp Ophthalmol. 2016;254(9):1731\u20136.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"2181_CR24","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/aos.12326","volume":"92","author":"K Schramm","year":"2014","unstructured":"Schramm K, Mueller M, Koch FH, Singh P, Kohnen T, Koss MJ. Effects of core vitrectomy in the treatment of age-related macular degeneration. Acta Ophthalmol. 2014;92(5):465\u201372.","journal-title":"Acta Ophthalmol"},{"issue":"7","key":"2181_CR25","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/j.ophtha.2009.11.007","volume":"117","author":"AB Roller","year":"2010","unstructured":"Roller AB, Mahajan VB, Boldt HC, Abramoff MD, Russell SR, Folk JC. Effects of vitrectomy on age-related macular degeneration. Ophthalmology. 2010;117(7):1381\u20136. https:\/\/doi.org\/10.1016\/j.ophtha.2009.11.007.","journal-title":"Ophthalmology"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-021-02181-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-021-02181-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-021-02181-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T17:49:26Z","timestamp":1639417766000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-021-02181-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2181"],"URL":"https:\/\/doi.org\/10.1186\/s12886-021-02181-1","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"17 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DATASUS databases are publicly available, and do not require approval from ethics committees, according to the Brazilian ethics Resolution n\u00b0 510\/2016 []. Also, no patient\u2019s consent is needed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Novartis sponsored the study but did not influenced scientific conduction. IQVIA received fees for the study conduction, including study design and concept, data acquisition and analysis, as well as writing the first draft of the manuscript; IQVIA did not receive fees for posteriori modifications (address and incorporate suggestions of the other authors).FFJ, LTF, MP and TP are Novartis employees. JCBO, MGB, and GSJ are IQVIA employees. CAMN and ACT declared no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"430"}}